About us

Coriolis is a globally operating service provider and one of the world leaders in formulation research and development of (bio)pharmaceutical drugs and vaccines.

As a privately-held and independent company with an interdisciplinary team of highly skilled scientists and an expert scientific advisory board, we provide cutting-edge services and tailor-made solutions for our clients.

Founded in 2008, Coriolis is the expert in the development of liquid and lyophilized formulations, process development for freeze-drying, as well as analytical services including GMP (Good Manufacturing Practice) and release analysis.

We have supported the successful development of many drug products and our scientists are eager to apply their experience on a large range of molecules (including proteins, peptides, monoclonal antibodies, nucleic acids, advanced therapy medicinal products (ATMPs), vaccines, viruses, virus-like particles and GMOs) to your project.

About Coriolis Pharma

 

Our facts & figures

#
top_solution
13+
years of experience in biopharma development
#
qualified_employees
140+
highly qualified employees
#
analytical_methods
100+
different analytical methods in house
#
laboratory
6900 m²
lab and office space incl. BSL-1/BSL-2 & GMP
#
peer_reviewed
130+
peer reviewed scientific publications
#
global_customers
725+
global customers from start-up to Big Pharma
#
projects_performed
1500+
projects performed successfully

Our milestones

our_approach
2008

Foundation of Coriolis Pharma

working_at_coriolis
2009

Move to the IZB (Innovation and Start-Up Center for Biotechnology) in Martinsried

gmp_analysis
2012

GMP accreditation

bio_safety_level
2016/17

Biological Safety Level (BSL) 1 & 2 certification

laboratory
2017

Move to new facilities in Martinsried

years_experience
2018

10th anniversary of Coriolis Pharma

virus-based_atmps
2021

Expansion into new facilities for ATMP development (up to BSL2)